RT Journal
A1 Schwab, Joseph H.
A1 Springfield, Dempsey S.
A1 Raskin, Kevin A.
A1 Mankin, Henry J.
A1 Hornicek, Francis J.
T1 What’s New in Primary Bone Tumors
JF The Journal of Bone & Joint Surgery
JO The Journal of Bone & Joint Surgery
YR 2012
FD October 17
VO 94
IS 20
SP 1913
OP 1919
DO 10.2106/JBJS.L.00955
UL http://dx.doi.org/10.2106/JBJS.L.00955
AB 
With regard to malignant tumors, much effort has been focused on finding new potential targets for systemic therapy. Additional efforts have been made in an attempt to identify disease markers that will correlate with outcome. For benign tumors, the focus has been on less aggressive treatment over time. For example, twenty-five years ago, giant cell tumor of bone was often treated with en bloc excision, whereas now, local curettage with or without an adjuvant is more routine. Presently, drugs that act on osteoclasts, such as denosumab (an antibody to RANK ligand), may result in management of giant cell tumors without surgery particularly with very large or recurrent tumors. We will review some of the newer aspects of detection and treatment of some of the more common primary malignant and benign bone tumors.